Clinical aspects of a phase I trial of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent

The antitumour action of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) is mediated through tumour-selective antivascular effects and cytokine induction. This clinical phase I trial was conducted to examine its toxicity, maximum tolerated dose, pharmacokinetics (PK) and pharmacodynamics (PD). A second...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Jameson, M B, Thompson, P I, Baguley, B C, Evans, B D, Harvey, V J, Porter, D J, McCrystal, M R, Small, M, Bellenger, K, Gumbrell, L, Halbert, G W, Kestell, P
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2003
Assuntos:
Clinical
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC2741109/
https://ncbi.nlm.nih.gov/pubmed/12799625
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6600992
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados